Baidu
map

Biochemia Medica:临床医生对关键风险结果的意见:在克罗地亚一家三级医院的调查

2019-11-03 MedSci MedSci原创

如果每个实验室修改其关键结果报告实践程序,则以反映其患者群体的临床需求。

如果每个实验室修改其关键结果报告实践程序,则以反映其患者群体的临床需求。这项调查的目的是评估克罗地亚医学生物化学家商会(CCMB)定义的关键实验室值与大学医院“ Sveti Duh”(克罗地亚萨格勒布)的医生的需求相符的程度。

我们对医院五个科室的医生进行了调查。询问医生关于关键风险结果的一般问题。本研究提供由CCMB定义的临界风险结果列表,要求医生修改现有的临界风险结果并建议添加新的参数。所得数据以数字表示。当观测值较低时,采用比值法。

研究发现,调查回复率为43%(52/121)。大多数人(48/52)希望通过个人(31/48)或同事(32/48)了解关键风险结果。他们更愿意了解凝血酶原时间、血小板计数、血红蛋白、葡萄糖、肌酐、钠和钾的关键风险结果。48名医生中有13名建议修订CCMB的关键风险结果列表。新生儿学家批准了CCMB的名单。

研究表明,尽管CCMB定义的大多数关键风险结果与我们医院医生的需求非常吻合,但仍需要进行一些修订以满足个别部门的特殊需求。因此,向要求实验室检测的人员通报关键风险结果的做法受到高度赞赏。

原始出处:

Pavica Šonjić,Ana NiklerClinicians opinion about critical risk results proposed by the Croatian Chamber of Medical Biochemists: a survey in one Croatian tertiary hospital

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

 


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1918911, encodeId=04221918911fe, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Sep 10 15:09:00 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1689561, encodeId=4a3616895613c, content=<a href='/topic/show?id=ad0619e19b0' target=_blank style='color:#2F92EE;'>#三级#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19719, encryptionId=ad0619e19b0, topicName=三级)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eeb28833546, createdName=luckyshitiancai_42705693, createdTime=Mon Dec 16 11:09:00 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859009, encodeId=5a751859009f8, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri Aug 28 15:09:00 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554798, encodeId=a35b1554e98d6, content=<a href='/topic/show?id=550522e2957' target=_blank style='color:#2F92EE;'>#临床医生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22729, encryptionId=550522e2957, topicName=临床医生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=453f14553881, createdName=xiaoyeshuang, createdTime=Tue Nov 05 02:09:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610084, encodeId=446f161008417, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Nov 05 02:09:00 CST 2019, time=2019-11-05, status=1, ipAttribution=)]
    2020-09-10 sunylz
  2. [GetPortalCommentsPageByObjectIdResponse(id=1918911, encodeId=04221918911fe, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Sep 10 15:09:00 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1689561, encodeId=4a3616895613c, content=<a href='/topic/show?id=ad0619e19b0' target=_blank style='color:#2F92EE;'>#三级#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19719, encryptionId=ad0619e19b0, topicName=三级)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eeb28833546, createdName=luckyshitiancai_42705693, createdTime=Mon Dec 16 11:09:00 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859009, encodeId=5a751859009f8, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri Aug 28 15:09:00 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554798, encodeId=a35b1554e98d6, content=<a href='/topic/show?id=550522e2957' target=_blank style='color:#2F92EE;'>#临床医生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22729, encryptionId=550522e2957, topicName=临床医生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=453f14553881, createdName=xiaoyeshuang, createdTime=Tue Nov 05 02:09:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610084, encodeId=446f161008417, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Nov 05 02:09:00 CST 2019, time=2019-11-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1918911, encodeId=04221918911fe, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Sep 10 15:09:00 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1689561, encodeId=4a3616895613c, content=<a href='/topic/show?id=ad0619e19b0' target=_blank style='color:#2F92EE;'>#三级#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19719, encryptionId=ad0619e19b0, topicName=三级)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eeb28833546, createdName=luckyshitiancai_42705693, createdTime=Mon Dec 16 11:09:00 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859009, encodeId=5a751859009f8, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri Aug 28 15:09:00 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554798, encodeId=a35b1554e98d6, content=<a href='/topic/show?id=550522e2957' target=_blank style='color:#2F92EE;'>#临床医生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22729, encryptionId=550522e2957, topicName=临床医生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=453f14553881, createdName=xiaoyeshuang, createdTime=Tue Nov 05 02:09:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610084, encodeId=446f161008417, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Nov 05 02:09:00 CST 2019, time=2019-11-05, status=1, ipAttribution=)]
    2020-08-28 jeanqiuqiu
  4. [GetPortalCommentsPageByObjectIdResponse(id=1918911, encodeId=04221918911fe, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Sep 10 15:09:00 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1689561, encodeId=4a3616895613c, content=<a href='/topic/show?id=ad0619e19b0' target=_blank style='color:#2F92EE;'>#三级#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19719, encryptionId=ad0619e19b0, topicName=三级)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eeb28833546, createdName=luckyshitiancai_42705693, createdTime=Mon Dec 16 11:09:00 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859009, encodeId=5a751859009f8, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri Aug 28 15:09:00 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554798, encodeId=a35b1554e98d6, content=<a href='/topic/show?id=550522e2957' target=_blank style='color:#2F92EE;'>#临床医生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22729, encryptionId=550522e2957, topicName=临床医生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=453f14553881, createdName=xiaoyeshuang, createdTime=Tue Nov 05 02:09:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610084, encodeId=446f161008417, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Nov 05 02:09:00 CST 2019, time=2019-11-05, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1918911, encodeId=04221918911fe, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Sep 10 15:09:00 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1689561, encodeId=4a3616895613c, content=<a href='/topic/show?id=ad0619e19b0' target=_blank style='color:#2F92EE;'>#三级#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19719, encryptionId=ad0619e19b0, topicName=三级)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eeb28833546, createdName=luckyshitiancai_42705693, createdTime=Mon Dec 16 11:09:00 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859009, encodeId=5a751859009f8, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri Aug 28 15:09:00 CST 2020, time=2020-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554798, encodeId=a35b1554e98d6, content=<a href='/topic/show?id=550522e2957' target=_blank style='color:#2F92EE;'>#临床医生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22729, encryptionId=550522e2957, topicName=临床医生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=453f14553881, createdName=xiaoyeshuang, createdTime=Tue Nov 05 02:09:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610084, encodeId=446f161008417, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Nov 05 02:09:00 CST 2019, time=2019-11-05, status=1, ipAttribution=)]

相关资讯

抗高血压药的用药禁忌,临床医生须谨记

高血压病是中老年人常见的一种慢性疾病,除了改善患者的饮食习惯及生活方式外,应使用抗高血压药物进行长期或终生治疗。抗高血压药物种类较多,如应用不当不仅达不到治疗目的,更有可能引起多种副作用或不良反应。下面就来介绍下临床上常用的一线降压药的用药禁忌及注意事项。敲黑板,划重点!一、利尿剂其降压机制是利钠排水,使高血容量负荷降低而发挥降压作用。包括袢利尿剂、噻嗪类利尿剂以及保钾利尿剂。代表药物有氢氯噻嗪、

人工智能并不能取代临床医生

在未来的一些年里,你可能会第一次与医学人工智能(AI)系统进行互动,能够自动驾驶汽车、家庭语音助手以及自我标签的图片库的相同技术如今在卫生保健领域取得了快速的发展,而首个医学人工智能系统(AI)如今已经开始转向临床应用了。

张力教授:临床医生除了看好病,科研也不能落下

由北京白求恩公益基金会主办的“白求恩·中青年医生优才培养计划项目”科研培训上海站隆重召开。本次培训课程围绕临床医生在临床研究创新思路的寻找、研究设计、数据库建设、统计分析、文章写作与最终科研成果发表等一系列各方面存在的误区,可能遇到的问题,结合实例展开整个课程,以期为肺癌领域临床专家解决科研道路上的实际问题。

临床医生要不要做科研?在黄晓军看来这不是问题

临床医生要不要做科研?这是个问题。但在北京大学人民医院黄晓军看来,这不是个问题。

王拥军教授:从临床医生到临床科学家的关键几步

有人把医生依照能力水平分为三个层次:合格的临床医生、杰出的学科带头人和卓越的临床科学家,可见临床科学家应该是很多医生努力的终极目标。首都医科大学附属北京天坛医院王拥军教授及其团队连续六年是国际卒中领域顶级杂志《stroke》收录论文最多的单中心,他们的临床研究质量和数量均达到国际一流水准,得到国内外同行的高度认可。近日,他领衔打造了临床科学家训练营,旨在培训临床医生获得更高的临床科研能力。对于

是否所有ICU临床医生都需要定期进行倦怠测试? 是

ICU的入院是非计划的紧急情况,需要ICU专业人员迅速处理伴有不确定结果的复杂情况,当处理患者和家人医疗危机时,专业团队陷入了一种高度紧张和强烈情绪的复杂环境中,随着对高级维持生命治疗技术的要求日益提高,工作环境越来越复杂。越来越多的证据表明,ICU护士和医生的职业倦怠是这种不可避免的高压力工作环境要求的直接后果。严重的职业倦怠相关症状非常普遍,已有1/3的ICU护理人员和1/2的ICU被报道

Baidu
map
Baidu
map
Baidu
map